Leticia Soriano

Mrs. Leticia Soriano

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LSLuis Sánchez-Guillén
Luis Sánchez-Guillén
LSLeticia Soriano
Leticia Soriano
FLFrancisco López-Rodríguez-Arias
Francisco López-Rodríguez-Arias
Xavi BarberXavi Barber
Xavi Barber
AMAna Murcia
Ana Murcia
ASAntonio Arroyo Sebastián
Antonio Arroyo Sebastián
Background: Peripheral parenteral nutrition allows repletion of acute nutrient deficiencies and could prevent further nutrition deficits before and after colorectal surgery. A randomized open study was performed to evaluate the effect of perioperative peripheral parenteral nutrition (PPN) support on postoperative morbidity after colorectal cancer surgery within an enhanced recovery program. Methods: Patients were randomized into two groups: peripheral parenteral nutrition (PPN) (with Peri-Olimel N4-E) versus conventional fluid therapy (FT). Ninety-day postoperative complications, laboratory parameters, length of hospital stay, and compliance with the ERAS protocol were assessed. Results: A total of 158 patients were analysed. The overall 90-day complication rate was 38.6% (61 patients), and 24 patients had major complications (Clavien–Dindo III–V) (15.2%). In the multivariate analysis, the intervention (PPN vs. FC) showed a protective effect against postoperative complications (p = 0.0031, OR = 0.2 (CI: 0.08–0.87)). Following ordinal regression, PPN and early oral tolerance showed a protective effect, being less likely to develop complications or to move from minor to major complications. In patients with low compliance to ERAS during the first postoperative day, PPN showed a protective effect, preventing 28% of morbidity. Conclusions: Perioperative peripheral parenteral nutrition (PPN) support with Peri-Olimel N4-E in colorectal cancer surgery associated with early oral intake could reduce postoperative complications.

18 September 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
FLFrancisco López-Rodríguez-Arias
Francisco López-Rodríguez-Arias
LSLuis Sánchez-Guillén
Luis Sánchez-Guillén
CLCristina Lillo-García
Cristina Lillo-García
VOVerónica Aranaz Ostáriz
Verónica Aranaz Ostáriz
MAM José Alcaide
M José Alcaide
ASAntonio Arroyo Sebastián
Antonio Arroyo Sebastián
Background: A poor body composition (BC) has been identified as a risk factor for patients with colorectal cancer (CRC). This study was performed to assess the effect of early peripheral parenteral nutrition (PPN) on BC in patients undergoing CCR surgery within an enhanced recovery program. Methods: Patients with normal nutritional status were prospectively included between October 2016 and September 2019, randomized into two groups (PPN with periOlimel N4-E versus conventional fluid therapy) and subsequently classified according to their preoperative CT scan into high- or low-risk BC groups. Postoperative complications and length of hospital stay (LOS) were assessed. Results: Of the 156 patients analyzed, 88 patients (56.4%) were classified as having high-risk BC according to CT measurements. PPN led to a 15.4% reduction in postoperative complications in high-risk vs. 1.7% in low-risk BC patients. In the multivariate analysis, high-risk BC was related to an OR (95% CI) of 2 (p = 0.044) of presenting complications and of 1.9 (p = 0.066) for major complications, and was associated with an increase in LOS of 3.6 days (p = 0.039). Conclusions: The measurement of patients’ BC can allow for the identification of target patients where PPN has been proven to be an effective tool to improve postoperative outcomes.

1 June 2014 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
FRFrancisco José Rodríguez-Lucena
Francisco José Rodríguez-Lucena
LSLeticia Soriano
Leticia Soriano
CCCarmen Matoses- Chirivella
Carmen Matoses- Chirivella
IJInmaculada P. Jiménez-Pulido
Inmaculada P. Jiménez-Pulido
JMJosé M. del Moral-Sánchez
José M. del Moral-Sánchez
ANAndrés Navarro-Ruiz
Andrés Navarro-Ruiz
Febrile neutropenia is a cause of dose reduction in hematological cancer treatments, with patient risk of infection proportional to duration and severity. In addition, colony-stimulating factors have been shown to be beneficial in a patient subgroup, although they are probably overused in the clinical setting.